GTG.AX - Genetic Technologies Limited

ASX - ASX Delayed Price. Currency in AUD
0.009
0.000 (0.00%)
At close: 3:36PM AEST
Stock chart is not supported by your current browser
Previous Close0.009
Open0.009
Bid0.009 x 0
Ask0.010 x 0
Day's Range0.009 - 0.009
52 Week Range0.006 - 0.021
Volume466,681
Avg. Volume5,783,420
Market Cap22.897M
Beta2.05
PE Ratio (TTM)N/A
EPS (TTM)-0.003
Earnings DateMar 1, 2016 - Mar 5, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.25
  • GlobeNewswire7 days ago

    Genetic Technologies Secures A$20 Million Equity Placement Facility

    Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position. Under the Facility, Kentgrove Capital may provide the Company with up to A$20 million of equity capital in a series of individual placements of up to $1 million (or a higher amount by mutual agreement) over the next 20 months.

  • GlobeNewswire13 days ago

    Genetic Technologies Formalises Strategic Alliance with Blockchain Global

    Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Framework Agreement (“Agreement”) with Blockchain Global Limited ACN 601 628 497 (“BCG”).

  • GlobeNewswire16 days ago

    Genetic Technologies Announces Appointment of Swisstec as Non-Exclusive Asian Distributor

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”).  This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia.

  • ACCESSWIRE29 days ago

    Today’s Research Reports on Stocks to Watch: Genetic Technologies and Innovate Biopharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Genetic Technologies saw big gains on news that its breast cancer and colorectal cancer risk assessment tests are on track. Shares of Innovate were headed in the opposite direction on news that the company has filed a securities registration statement amendment with the SEC to issue up to $175 million of new stock and to sell 14 million shares of existing stock. Innovate Biopharmaceuticals, Inc.

  • Genetic Technologies Stock Up on Genetic Test Update
    Market Realistlast month

    Genetic Technologies Stock Up on Genetic Test Update

    Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Coda Octopus Group, Inc. (NASDAQ: CODA ) stock soared ...

  • GlobeNewswirelast month

    Genetic Technologies Limited Announces Expansion of Genetic Risk Assessment Tests and October Launch of New Breast Cancer and Colorectal Cancer Tests

    MELBOURNE, Australia, July 16, 2018-- Genetic Technologies Limited, a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that ...

  • GlobeNewswire2 months ago

    Genetic Technologies Announces Heads of Agreement with Swisstec

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. (“Swisstec”) to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”). The JV Company will enable both companies to collaborate to develop a service platform using blockchain technology that will provide a marketplace for medical services and personalised health management, and will also facilitate data management and AI-based services to promote better patient outcomes.

  • GlobeNewswire2 months ago

    Genetic Technologies Announces Binding Project Shivom Agreement

    Project Shivom to provide GTG access to a significant pool of data, particularly related to the Indian population. GTG, through access to the Indian population data to modify its risk assessment kits as well as to develop new Indian specific tests or products, including tests related to diabetes and other disease, based on opportunity and areas of need.

  • PR Newswire5 months ago

    Shivom Partnership With Genetic Technologies Will Enable Better Cancer Prediction and Prevention Through Mass Genomic Data Analysis

    NASDAQ: GENE) to accelerate the prediction of cancer for millions of individuals worldwide. GTG, whose lead product is BREVAGenplus® - a clinically validated risk assessment test for non-hereditary breast cancer - is at the forefront of preventive medicine.

  • Benzinga7 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Helios and Matheson Analytics Inc (NASDAQ: HMNY ) ...